冻干重组人脑利钠肽治疗急性左心功能衰竭患者的临床观察

发布时间：2019-07-16 18:01

【摘要】：目的:观察冻干重组人脑利钠肽治疗急性左心功能衰竭的临床疗效及安全性。方法:将60例急性左心功能衰竭患者,按随机数字表法分为观察组和对照组,各30例。对照组患者给予吸氧、利尿、强心、扩张血管、控制心律失常及抑制心室重构等常规治疗;观察组患者在对照组基础上加用冻干重组人脑利钠肽注射液1.5μg/kg静脉推注,然后以0.007 5μg/(kg·min),ivgtt,72 h。观察两组患者临床疗效及治疗前后左心室舒张末期内径(LVDD)、左心室射血分数(LVEF)、肾上腺素(E)、去甲肾上腺素(NE)、肾素活性(PRA)、血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD)水平,并记录其不良反应。结果:观察组患者总有效率明显高于对照组(83.33%vs.60.00%),差异有统计学意义(P0.05)。治疗前,两组患者LVDD、LVEF、E、NE、PRA、AngⅡ、ALD水平比较,差异无统计学意义(P0.05);治疗后,两组患者上述指标均显著改善,且观察组改善程度显著优于对照组,差异均有统计学意义(P0.05);两组患者均未见明显不良反应发生。结论:冻干重组人脑利钠肽治疗急性左心功能衰竭疗效显著,且安全性较好。
[Abstract]:Objective: to observe the clinical efficacy and safety of freeze-dried recombinant human brain natriuretic peptide in the treatment of acute left ventricular failure. Methods: sixty patients with acute left ventricular failure were randomly divided into observation group (n = 30) and control group (n = 30). The patients in the control group were given routine treatment such as oxygen inhalation, diuresis, cardiotonic strength, vasodilation, control of arrhythmia and inhibition of ventricular remodeling, while the patients in the observation group were injected intravenously with lyophilized recombinant human brain natriuretic peptide injection 1.5 渭 g / kg and then 0.007 5 渭 g / (kg 路min), ivgtt,72 h). The clinical efficacy and left ventricular end-diastolic diameter (LVDD), left ventricular ejection fraction (LVEF), adrenalin (E), norepinephrine (NE), renin activity (PRA), angiotensin 鈪，

本文编号：2515183